抗慢性淋巴细胞白血病新药ofatumumab

A new drug for treating chronic lymphocytic leukemia,ofatumumab

导出

摘要 Ofatumumab(商品名ArzerraTM,也称HuMax-CD20TM)是一种针对B-细胞细胞膜上CD20分子的人源单克隆抗体。2009年10月美国FDA批准其用于治疗慢性淋巴细胞白血病。Ⅱ/Ⅲ期临床试验证明ofatumumab还可有效治疗非霍奇金淋巴瘤和类风湿关节炎。文中对ofatumumab的药效学、药代动力学、临床评价及安全性等做一综述,并对其在治疗非霍奇金淋巴瘤和类风湿关节炎中的疗效和安全性进行了简单介绍。 Ofatumumab （ Arzerra^TM, or HuMax-CD20^TM） , a fully human antibody targeting the CD20 tool-ecule in the cell membrane of B-cells, was approved by the US FDA for the treatment of chronic lymphocytic leukemia. Phase II/III trials demonstrated that ofatumumab was also effective in treating non-Hodgkin＇s lymphoma （NI-IL） and rheumatoid arthritis （ RA）. In this article, pharmacological effects, pharmacokinetics, clinical trials and safety of ofatumumab were reviewed. Its application in the treatment of NHL and RA was also discussed.

作者王彦妮

机构地区美国生物医药信息公司

出处《中国新药杂志》 CAS CSCD 北大核心 2012年第1期31-35,共5页 Chinese Journal of New Drugs

关键词全人源抗体 OFATUMUMAB 慢性淋巴细胞白血病非霍奇金淋巴瘤类风湿关节炎 fully human antibody ofatumumab chronic lymphocytic leukemia non-Hodgkin＇s lympho- ma rheumatoid arthritis

分类号 R979.1 [医药卫生—药品]

引文网络
相关文献

参考文献27

1HALLEK M, CHESON BD, CATOVSKY D, et hi. Guidelines for the diagnosis and treatmenl of chronic lymphocytic leukemia: a report from the International workshop on chronic lylnphocyticleukemia updating the national cancer institute-working group 1996 guidelines [ J ]. Blood, 2008, 111 ( 12 ) :5446 - 5456.
2O'BRIEN S, OSTERBORG A. Ofatumumab: a new CD20 mono- clonal antibody therapy for B-cell chronic lymphocytic leukemia[ J]. Clin Lymphoma Myeloma Leuk, 2010,10 (5) :361 - 368.
3NELSON AL, DHIMOLEA E, REICHERT JM. Development trends for human monoclonal antibody therapeutics[ J]. Nat RevDrug Discov, 2010,9(10) :767 -774.
4QUINTAS-CARDAMA A, O'BRIEN S. Targeted therapy for chro- nic lymphocytic leukemia[J]. Target Oncol, 2009, 4(1) :11 - 21.
5JAGLOWSKI SM, ALINAR1 L, LAPALOMBELLA R,et al. The clinical application of monoclonal antibodies in chronic lympho-cytie leukemia[ J]. Blood ,2010, 116(19) :3705 - 3714.
6LEMERY SJ, ZHANG J, ROTHMANN MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatmentof patients with chronic Iyinphoeytic leukemia refractory to fludarabine and alemtuzumab [J]. Clin Cancer Res, 2010, 16 (17) :4331 -4338.
7GRAVANIS I, ERSBOLL J, SKOVLUND E, et al. The Europe- an Medicines Agency review of ofatumumab ( Arzerra ) for the treatment of chronic lymphocytic leukemia in patients refractory tofludarabine and alemtuzumab: summary ment of the European medicines agency products for human use[ J]. Oncologist 1343. of the scientific assess- committee for medicinal 2010,15(12) :1335.
8TEELING J, MACKUS W, WIEGMAN L,et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20[J]. Jlmmunol, 2006, 177(1):362-371.
9GSK. Prescribing information [ EB/OL ]. (2011 - 03 - 22 ). http ://www. arzerra, com/pdf/AZA146, pdf.
10BEUM PV, L1NDORFER MA, BEURSKENS F, et al. Comple- ment activation on B lymphocytes opsonizcd with rituximab or ofatumumab produces substantial changes in membrane structurepreceding cell lysis [ J ]. J lmmunol, 2008,181 ( 1 ) :822 - 832.

1治疗慢性淋巴细胞白血病的新药Arzerra获准上市[J].中国执业药师,2009(12):54-54.
2徐芳媛,邢爱敏.用于非霍奇金淋巴瘤的Arzerra[J].药学进展,2010,34(1):48-48.
3美国批准慢性淋巴细胞白血病治疗新药[J].中国处方药,2009(12):52-52.
4孙大柠.靶向CD20的单克隆抗体——Ofatumumab[J].药学进展,2008,32(3):140-140.
5梁晓丽,裴艺芳,姜文亮,封宇飞,孙春华.抗肿瘤新药——奥伐单抗[J].中国药学杂志,2012,47(16):1341-1342.
6骆毅（摘）.Ofatumumab进入Ⅲ期临床试验[J].国外药讯,2008(3):36-36.
7GSK／Genmab递交Arzerra的申请[J].国外药讯,2009(2):25-26.
8雷兵团,胡跃民,李岩峰.全人源化靶向抗CD20单克隆抗体ofatumumab[J].医药导报,2010,29(9):1189-1191. 被引量：3
9GSK单抗药Arzerra sBLA获FDA批准[J].临床合理用药杂志,2014,7(32):75-75.
10GSK单抗药Arzerra sBLA获FDA批准[J].中国医药技术经济与管理,2014(2):16-17.

中国新药杂志

2012年第1期

浏览历史

内容加载中请稍等...

抗慢性淋巴细胞白血病新药ofatumumab

参考文献27

相关作者

相关机构

相关主题

浏览历史